Corpus ID: 41035506

Randomized Controlled Trial of Desonlde Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis.

@article{Trookman2011RandomizedCT,
  title={Randomized Controlled Trial of Desonlde Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis.},
  author={N. S. Trookman and R. Rizer},
  journal={The Journal of clinical and aesthetic dermatology},
  year={2011},
  volume={4 11},
  pages={
          34-8
        }
}
  • N. S. Trookman, R. Rizer
  • Published 2011
  • Medicine
  • The Journal of clinical and aesthetic dermatology
  • OBJECTIVE Desonide hydrogel 0.05%, an effective treatment for mild-to-moderate atopic dermatitis, is United States Food and Drug Administration approved as a treatment for patients as young as three months of age. Previous studies have also demonstrated that this hydrogel formulation of desonide 0.05% improved moisturization and reduced transepidermal water loss. Increased skin hydration has been correlated with improved and sustained integrity of the epidermal barrier in patients with atopic… CONTINUE READING
    13 Citations
    Hydrogels for Atopic Dermatitis and Wound Management: A Superior Drug Delivery Vehicle
    • 21
    • PDF
    Vehicles for atopic dermatitis therapies: more than just a placebo.
    Lichen Simplex Chronicus Secondary to Scald Injury and Skin Flap Transplantation